13. Coagulation Disorders and Modifiers

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/33

encourage image

There's no tags or description

Looks like no tags are added yet.

34 Terms

1
New cards

Factor V Leiden disease

  • inherited genetic disorder (most common inherited thrombophilia)

  • mutation in factor V → resistance to activated Protein C → decreased activation of factor V

  • increased risk for DVT/PE


2
New cards

Antiphospholipid Syndrome (APS)

  • autoantibodies that promote clot formation

  • venous/arterial thrombosis and recurrent pregnancy loss


3
New cards

Acquired risk factors for DVT/PE

  • cancer

  • pregnancy/estrogen

  • immobility

  • surgery


4
New cards

Pathophysiology of Hypercoagulability

↑ thrombin → ↑ fibrin → pathologic clot formation


vascular obstruction → decreased perfusion → ischemia or infarction

5
New cards

Clinical manifestations of DVT

  • unilateral leg swelling

  • pain

  • warmth

  • redness


6
New cards

Clinical manifestations of PE

  • sudden dyspnea

  • chest pain

  • tachycardia


7
New cards

Managing & preventing PE/DVT

  • Anticoagulants

  • early ambulation, compression devices, hydration, smoking cessation

  • Nursing Priorities → monitor for thrombosis, bleeding, and treatment complications


8
New cards

Antithrombotic Therapy

Used to prevent or treat harmful blood clot formation

Reduces platelet aggregation, inhibits clotting factors, or dissolves fibrin clots

  • antiplatelets

  • anticoagulants

  • thrombolytics


9
New cards

Aspirin

Cox -1 inhibitor anti-platelet

  • irreversibly inhibits cox-1 → ↓ thromboxane A → ↓ platelet activation + aggregation

  • PO

  • major ADR: Bleeding, GI irritation/ulcers


Safety: avoid with active bleeding, Reye syndrome risk in children with viral illnesses


10
New cards

Clopidogrel

P2Y12 receptor inhibitor anti-platelet

  • blocks p2y12 receptors → ↓ platelet activation and aggregation

  • PO

  • major ADR: bleeding/hemorrhage


BLACK BOX WARNING: reduced effectiveness in CYP2C19 poor metabolizers


11
New cards

Nursing priorities for anti-platelet therapy

MONITOR: bleeding, bruising, black/tarry stools

INTERACTIONS: NSAIDs/anticoagulants → ↑ bleeding risk

TEACHING: do not stop prescribed therapy without provider instructions

12
New cards

Antiplatelets

prevent platelet aggregation → help prevent arterial clots

13
New cards

Eptifibatide

GP IIb/IIa inhibitor anti-platelet

  • blocks GP IIb/IIa receptors → prevents fibrinogen binding → ↓ platelet aggregation

  • IV

  • clinical use: ACS and other selected coronary interventions

  • major ADR: severe bleeding; thrombocytopenia


Nursing priorities:

  • monitor bleeding, platelet count, hemoglobin/hematocrit

  • assess IV for bleeding/hematoma

  • renal function may require dose adjustment

  • avoid unnecessary invasive procedures

  • report significant bleeding


14
New cards

Unfractionated Heparin (UPH)

Heparin

  • inhibits factor Xa and thrombin (IIa)

  • IV or SC → rapid anticoagulation

  • major ADR: bleeding, Heparin-induced thrombocytopenia (HIT)

  • monitor aPTT or anti-Xa, platelets

  • antidote: protamine sulfate


15
New cards

Low-Molecular-Weight Heparin (LMWH)

Enoxaparin

  • mainly inhibits Factor Xa

  • SC → rotate abdominal injection sites; do not rub

  • major ADR: bleeding; HIT less common

  • monitoring: platelets and renal function; no routine aPTT needed

  • reversal: protamine sulfate → partial reversal


16
New cards

Nursing Safety for Heparins

  • monitor bleeding

  • avoid IM injections

  • black box → spinal/epidural bleeding → possible paralysis


17
New cards

Heparin-Induced Thrombocytopenia (HIT)

Serious immune reaction to heparin

↑ platelet activation → ↑ blood clots (thrombosis)


key findings: > 50% drop in platelets from baseline → usually 5-10 days after starting heparin

S+S: new DVT/PE, limb pain/ischemia, skin necrosis


18
New cards

Nursing priorities for HIT

  • monitor platelet trends → > 50% decrease = suspect HIT

  • stop all heparin and notify provider immediately

  • start alternative non-heparin anticoagulant

  • avoid LMWH and routine platelet transfusions in acute HIT


19
New cards

Warfarin

Vitamin K antagonist

  • blocks vitamin K recycling → ↓ production of clotting factors II, VII, IX, X

  • PO → delayed anticoagulant effect

  • major ADR: bleeding/hemorrhage

  • black box: major or fatal bleeding

  • contraindications: active major bleeding; generally avoided in pregnancy


interactions: many medications and changes in vitamin K intake affect INR


20
New cards

Warfarin nursing priorities

Monitor PT/INR → usually 2-3

Maintain consistent vitamin K intake

antidote: vitamin K

teaching: regular INR checks; report bleeding

21
New cards

Direct Oral Coagulants (DOACs)

Includes Apixaban (Eliquis) and Dabigatran

monitoring: bleeding, CBC, kidney function → no INR or aPTT

interactions: NSAIDs/Aspirin ↑ bleeding risk

black box: stopping early → ↑ Thrombosis risk; spinal/epidural bleeding risk

teaching: DO NOT stop abruptly; take consistently!

22
New cards

Apixaban (Eliquis)

Factor Xa inhibitor → ↓ Thrombin formation

  • PO usually twice daily

  • major ADR: bleeding/hemorrhage

  • reversal: 4-factor PCC may be used for severe bleeding per protocol


23
New cards

Dabigatran

Blocks thrombin (IIa) → ↓ Fibrin formation

  • PO usually twice daily

  • major ADR: bleeding/hemorrhage

  • reversal: Idarucizumab → specific antidote


24
New cards

Nursing Considerations for all Anticoagulants

  • assess for bleeding → bruising, bleeding gums, hematuria, black/tarry stools

  • monitor for thrombosis → leg swelling/pain, sudden dyspnea, chest pain

  • avoid NSAIDs / aspirin

  • bleeding precautions → soft toothbrush, fall risks

  • before procedures → notify provider, maybe hold med

  • educate to take exactly as prescribed

  • immediately report uncontrolled bleeding or signs of DVT/PE


25
New cards

Alteplase

Fibrinolytic

  • converts plasminogen → plasmin → breaks down fibrin → dissolves existing clots

  • IV

  • acute ischemic stroke, PE, MI

  • major ADR: severe bleeding, intracranial hemorrhage

  • contraindications: active bleeding, intracranial hemorrhage, other bleeding risks


26
New cards

Von Willebrand Disease (vWD)

Inherited deficiency or dysfunction of von Willebrand factor

impaired platelet adhesion!

signs: easy bruising, nose bleeds, heavy menses, ↑ bleeding after surgery/injury

trtmt: depends on type/severity → desmopressin, vWF concentrate, antifibrinolytics

27
New cards

Clotting factor deficiencies

Hemophilia A → factor VIII

Hemophilia B → factor IX

  • X-linked bleeding disorders affecting intrinsic pathway

  • prolonged bleeding/easy bruising

  • hemarthrosis → joint pain ad swelling

  • factor replacement


28
New cards

Immune Thrombocytopenia (ITP)

Acquired autoimmune destruction of platelets

  • CBC shows low platelets

  • petechiae, purpura, mucosal bleeding, nose bleeds, gum bleeding


29
New cards

Disseminated Intravascular Coagulation (DIC)

Widespread clotting consumes platelets and clotting factors, resulting in bleeding

  • too much clotting = bleeding

  • bleeding, bruising, thrombosis, organ ischemia, shock

  • treat underlying cause, and then supportive care like platelets


30
New cards

Hemostatic Therapy

Used to prevent or control excessive bleeding caused by impaired clot breakdown

Promotes hemostasis through 2 major actions

  • ↑ clotting factor availability → more clots made

  • ↓ fibrinolysis → less clot breakdown


Can cause thromboembolic complications in susceptible patients


31
New cards

Desmopressin (DDAVP)

Synthetic ADH analog → hemostatic agent

  • stimulates V2 receptors → release of vWF and factor VIII → clot formation

  • IV, SC, intranasal

  • mild hemophilia A or von Willebrand Disease

  • ADR: hyponatremia, water intoxication, headache, flushing

  • contraindications: hyponatremia, renal impairment, some cardiac conditions


32
New cards

Desmopressin nursing considerations

Monitor serum sodium, fluids balance, urine output

Fluid restriction

assess headache, confusion, weight gain → hyponatremia

monitor response to therapy, repeated dose may ↓ effect over time

33
New cards

Transexamic Acid (TXA)

Blocks plasminogen binding to fibrin → ↓ Fibrin breakdown

  • PO, IV, topical

  • trauma, surgery, postpartum hemorrhage, heavy menses, epistaxis

  • seizures (high dose), hypotension (rapid IV), thrombotic complications


34
New cards

Aminocaproic Acid

Inhibits plasminogen activation → ↓ Plasmin → ↓ Fibrin breakdown

  • PO/IV

  • surgical bleeding, excessive fibrinolysis, hemophilia-related bleeding

  • hypotension (rapid IV), myopathy, thrombotic complications